Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
August 21, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Advisory Committee Meeting Scheduled for October 31, 2024; PDUFA Goal Date Remains December 20, 2024 Lexicon Seeks Approval for ZYNQUISTA™ (sotagliflozin) as an Adjunct to Insulin Therapy for...
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
August 13, 2024 08:30 ET
|
Lexicon Pharmaceuticals, Inc.
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™ Efforts Expected to Reduce 2025 Operating Costs by $40 Million ...
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
August 07, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual...
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 01, 2024 16:00 ET
|
Lexicon Pharmaceuticals, Inc.
INPEFA® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20,...
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
July 25, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the...
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
July 16, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type...
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
July 15, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings...
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
July 08, 2024 09:15 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief...
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
June 21, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and...
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
June 19, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators...